Currently, an ongoing phase I clinical trial is using lyso-thermosensitive liposomal doxorubicin (LTLD, ThermoDox; Celsion Corporation, NJ, USA) to achieve higher local drug concentrations in metastatic HER2-negative breast cancer patients (NCT03749850) [143]. The gene discussed is ERBB2; the disease is breast cancer.